agilon health, inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against agilon health, inc. (AGL).

If you purchased or held agilon health securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About agilon health, inc.

Agilon health, inc. partners with primary care physicians to provide value-based care for senior patients, particularly those enrolled in Medicare Advantage plans. The company’s business model centers on managing the health outcomes and costs for these patient populations, working closely with healthcare providers to improve care quality and efficiency.

Over the past year, the company’s stock price has experienced substantial volatility, reflecting investor concerns about its financial performance, risk-adjustment revenue processes, and management changes.

Concerns Under Investigation

Lawyers are currently investigating whether agilon health may have made misleading statements or omitted material information regarding its financial performance and future outlook during the period between Feb. 25, 2025, and Aug. 4, 2025. This investigation is focused on several key events and disclosures that may have impacted investors.

On Aug. 4, 2025, after the market closed, agilon health reported its second quarter 2025 results, revealing a significant downturn in financial performance. Revenue dropped to $1.40 billion from $1.48 billion year-over-year, and the company’s medical margin swung from a positive $106 million in the prior year to a negative $53 million. In addition, agilon health withdrew its 2025 financial guidance, a move that surprised many investors.

These disclosures triggered a sharp reaction in the stock market. After a brief rise in after-hours trading, agilon health’s stock price plunged approximately 25% the next day, falling from around $2.20 to $1.60. This drop erased hundreds of millions of dollars in market value, deepening losses for investors who had already seen the stock decline by over 70% year-over-year.

A central focus of the investigation is the sequence of corrective disclosures. On Aug. 4, 2025, management acknowledged that updated premium data showed risk-adjustment revenues for 2024 and 2025 were overstated, leading to an $85 million cumulative write-down. During the earnings call, Executive Chair Ron Williams identified two main drivers of the shortfall: “final 2024 payer data… indicated our risk adjustment last year was lower than we previously assumed” and, due to this lower baseline and “enhanced data platform,” “our 2025 risk adjustment is trending lower than expected.” The company also announced the withdrawal of its 2025 guidance on the same call.

Attorneys might examine whether prior statements by agilon health and its executives misrepresented the company’s financial health and prospects. For example, in the Q4 2024 earnings release on Feb. 25, 2025, the company issued optimistic 2025 guidance, projecting revenues of $5.83–6.03 billion and a medical margin of $275–325 million. CEO Steve Sell stated that agilon health had “established a stronger foundation for success” and was focused on “long-term sustainable performance”. On May 6, 2025, during the Q1 2025 call, the company reaffirmed this full-year guidance, with Sell describing 2025 as a “transition year… and an inflection year” while expressing confidence in agilon health’s model. These statements may be scrutinized in light of later revelations that risk-adjustment revenues were far lower than previously assumed.

Legal professionals may review whether shareholders were adequately informed about the risk of lower risk-adjustment revenues or the possibility of a significant write-down. The investigation might look into whether the company’s SEC filings through June 2025 provided any warning of these material issues. Investors only learned about the actual risk-adjustment trends and the $85 million write-down during the Aug. 4, 2025, earnings call.

The investigation may also consider the timing of CEO Sell’s resignation, which coincided with the Aug. 4, 2025, disclosures. This leadership change, along with the magnitude of the write-down and the insider sales, could be reviewed as potential indicators of knowledge or intent regarding the financial issues.

Your Rights and Next Steps

This is an active investigation into potential securities law violations by agilon health and certain executives. If you purchased or held agilon health securities between Feb. 25, 2025, and Aug. 4, 2025, and experienced financial losses, you may have the right to participate in any future class action lawsuit that could arise from these findings.

Securities attorneys could be looking into whether investors were misled about the company’s financial health, risk-adjustment revenues, and future outlook. If these concerns lead to a class action lawsuit, eligible investors may be able to recover a portion of their losses.

It is important to act promptly, as securities investigations and potential class actions are time-sensitive. By joining the investigation now, you can help ensure your rights are protected and that you are kept informed about any developments or opportunities for compensation.

You May Be Entitled to Compensation

Investors who purchased agilon health securities and suffered losses during the period from Feb. 25, 2025, to Aug. 4, 2025, may be eligible to join this investigation and seek compensation. Time is critical in securities matters, as deadlines for joining any potential class action may apply.

Lawyers are ready to help assess your situation and guide you through the process. Complete the form below to join the investigation and learn more about your rights.